Iron Inhibitors
5 drugsAbout Iron
Iron is an essential element involved in oxygen transport, cellular respiration, and enzyme function, making it critical for numerous biological processes. Dysregulation of iron homeostasis can lead to various health problems.
Iron is a drug target with implications across various therapeutic areas. Currently, there is no genetic evidence data available linking iron to specific diseases, but its fundamental role makes it a compelling target.
Five FDA-approved small molecule drugs, including DEFEROXAMINE MESYLATE, DEFERASIROX, JADENU, JADENU SPRINKLE, and EXJADE, modulate iron levels. These drugs are currently categorized within the 'other' therapeutic area.
Top Iron Drugs
Three companies, Sun Pharma, Pfizer and Novartis, have approved drugs targeting iron.
The market is moderately concentrated, suggesting potential entry barriers for new competitors.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| JADENU | Novartis | 2015 | 2 |
| JADENU SPRINKLE | Novartis | 2017 | 2 |
Iron Drug Modality Landscape
Modalities
Routes of Administration
Iron is amenable to small molecule drugs, with oral options available for convenient dosing.
The modality landscape is underexplored, presenting a whitespace opportunity for novel modalities.
Iron Clinical Trials 56 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Iron. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 35 | 17 | 14 | 4 | 55% |
| Phase 3 | 7 | 4 | 1 | 2 | 80% |
| Phase 4 | 11 | 7 | 4 | 0 | 64% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Iron Drug Approval Timeline (2005 - 2017)
The first drug was approved in 2004, and the most recent in 2017, spanning 14 years.
The approval timeline suggests a potentially maturing market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Iron. A trial counts if an approved drug acting on Iron is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.